When CLL patients temporarily stop their BTK inhibitor for a procedure, they can experience a "disease flare" mimicking relapse. It is critical for clinicians to recognize this phenomenon and not misinterpret it as true disease progression, as symptoms typically resolve upon restarting the medication.

Data from both DLBCL and follicular lymphoma studies show that recent bendamustine exposure negatively impacts T-cell quality, leading to poorer CAR T-cell therapy outcomes. This effect is most pronounced if the drug was given within a year of T-cell collection, making it a critical factor in long-term treatment sequencing.

Obinutuzumab infusions in CLL patients can cause severe reactions. A simple and effective mitigation strategy is to pre-treat the patient with a BTK inhibitor for as little as three days before the first infusion. This debulking effect significantly reduces infusion reaction risk and improves patient safety.

Platelet aggregation studies show riluzobrutinib does not impair platelet function. This unique profile suggests it may not need to be stopped before surgery, avoiding the risk of a perilous drop in platelet counts for ITP patients—a key differentiator from other BTK inhibitors.

When starting a BTK inhibitor for CLL, patients often experience a sharp increase in their lymphocyte count. This is not a sign of disease progression but a therapeutic effect as the drug forces malignant cells out of the lymph nodes. This effect typically normalizes over 6-8 weeks and should be explained to patients.

BTK inhibitors like ibrutinib can improve T-cell function. When combined with liso-cel CAR-T, this synergistic effect dramatically improves outcomes in heavily pretreated patients, increasing the complete response rate from 20% to 45% and the overall response rate from 48% to 86%.

Using a BCMA bispecific antibody first can exhaust a patient's T-cells or cause tumors to lose the BCMA target, rendering a subsequent BCMA-targeted CAR-T therapy ineffective. The optimal sequence is CAR-T first, which preserves T-cell function and BCMA expression, leaving bispecifics as a viable later-line option.

The landmark TRIANGLE trial has redefined frontline therapy for younger, fit mantle cell lymphoma patients. Adding a BTK inhibitor to induction and maintenance provides outcomes superimposable to those including an autologous stem cell transplant. This allows clinicians to omit the transplant, sparing patients significant toxicity without compromising efficacy.

BTK inhibitors block B-cell receptor signaling, causing long-surviving CLL cells to undergo programmed cell death (apoptosis) from a lack of stimulation. The common side effects are due to off-target kinase inhibition, not the intended BTK blockade itself, which has negligible action on other cells.